Asuragen – QuantideX BCR-ABL
Asuragen’s Precision Oncology Solutions.
Revolutionising Precision Oncology with QuantideX®: Where Sensitivity Meets Scalability
The QuantideX BCR-ABL Portfolio offers simple, reliable, ultra-sensitive quantitation of both the Major and Minor breakpoints. It allows any molecular laboratory to assess the deepest molecular response with unprecedented ease and deliver the results physicians and patients rely on.
QuantideX qPCR BCR-ABL IS Kit*
Confidently deliver results with Asuragen’s chronic myeloid leukaemia (CML) monitoring assay with BCR-ABL Major breakpoints (e13a2, e14a2). With direct reporting on the International Scale (IS) and deep clinical sensitivity of 0.002% (MR 4.7), laboratories can assess the deepest molecular response with unprecedented ease and deliver the results clinicians and patients rely on.
The QuantideX qPCR BCR-ABL IS Kit multiplex assay design and included analysis software render reporting CML monitoring results both accurate and quick, with results in ~4 hours.
QuantideX qPCR BCR-ABL minor Kit*
The BCR-ABL1 minor breakpoint (e1a2) constitutes a rare but distinct leukaemic variant and accurate detection and quantitation of these fusion transcripts are paramount to improving outcomes for all CML patients. The QuantideX qPCR BCR-ABL minor Kit enables ultra-sensitive detection of BCR-ABL1 minor fusion transcripts from whole blood specimens.
REDUCED COMPLEXITY
- Direct reporting on the International Scale (IS)+: Multi-point standard curve reduces variability and removes need for costly, complex sample exchange
- Single method, comprehensive reporting: QuantideX Reporter Software provides automated calculation of %IS’+, BCR-ABL1/ABL1 %ratio and ABL1 copy number^
OPTIMISED WORKFLOW
- Reduced hands-on time: Multiplexed design amplifies and detects both fusion and control genes in the same reaction
- Simplified inventory & quality management: All necessary RT and qPCR reagents and controls in a single, vendor-sourced kit to reduce QC burden
- Common workflows: Major & minor kits share common workflows to streamline testing and reduce risk of error
QUALITY PERFORMANCE
- Performance established using human RNA: Limits of Detection (LOD) of MR4.7 (0.002% IS) and LR4.61 (0.0025% ratio) confirmed in human RNA, not cell lines
- Multi-point Armored RNA®-based standards: Provide reproducible, traceable RNA quantitation values
- Increased analytical sensitivity without compromising analytical specificity: Unique Limit of Blank (LOB) approach used to minimise miscalling of non-leukaemic low positives
* Check the regulatory status in your country
+ QuantideX qPCR BCR-ABL IS Kit only
^ QuantideX qPCR BCR-ABL minor Kit only
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
